Neuroendocrine responses to levodopa in multiple system atrophy (MSA)
Hypothalamic dopaminergic pathways are involved in the regulation of growth hormone and prolactin release from the anterior pituitary. Neuroendocrine studies in patients with multiple system atrophy (MSA), in whom there is a reported loss of hypothalamic dopamine, are few and contradictory. We there...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 1999-11, Vol.14 (6), p.981-987 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 987 |
|---|---|
| container_issue | 6 |
| container_start_page | 981 |
| container_title | Movement disorders |
| container_volume | 14 |
| creator | Kimber, Jeffery Watson, Laura Mathias, Christopher J. |
| description | Hypothalamic dopaminergic pathways are involved in the regulation of growth hormone and prolactin release from the anterior pituitary. Neuroendocrine studies in patients with multiple system atrophy (MSA), in whom there is a reported loss of hypothalamic dopamine, are few and contradictory. We therefore studied the neuroendocrine responses to 250 mg levodopa (plus 25 mg carbidopa) in subjects with MSA (n = 15), and compared them with age‐ and sex‐matched healthy control subjects (n = 8). There were no significant differences in basal or post‐levodopa levels of growth hormone (GH), growth hormone‐releasing hormone (GHRH), glucose, insulin‐like growth factor (IGF‐1), or thyroid‐stimulating hormone (TSH) between the groups. In patients with MSA, basal levels of prolactin were elevated (21.1 ± 5.2 ng/mL [mean ± standard error]) compared with control subjects (12.1 ± 1.7, p |
| doi_str_mv | 10.1002/1531-8257(199911)14:6<981::AID-MDS1011>3.0.CO;2-W |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21160816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21160816</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4571-20f63807303707826d659bc270f2b83f539720223c6289fd04dac3e29c02b7553</originalsourceid><addsrcrecordid>eNqVkV1v0zAUQC0EYmXwF1AeENoeUnzt-CMFIXXdOiZtq9CA8nblJo7ISOJgNxv996RKGDzwwpMl6_j4-piQFOgUKGVvQHCINRPqCNI0BTiGZCbfpRpms_nFaXx1egMU4D2f0uli9ZbF60dk8nDmMZlQrUXMQYsD8iyEW9rDAuRTcgBU6EQqPiFn17bzzja5y3zZ2Mjb0Lom2BBtXVTZO5e71kRlE9VdtS3bykZhF7a2jszWu_bbLjq6upkfPydPClMF-2JcD8nn5dmnxYf4cnV-sZhfxlkiFMSMFpJrqjjliirNZC5FusmYogXbaF4InipGGeOZZDotcprkJuOWpRllGyUEPySvB2_r3Y_Ohi3WZchsVZnGui4gA5BUg-zBjwOYeReCtwW2vqyN3yFQ3LfFfSfcd8KhLUKCEvu2iH1bHNsiR4qLFTJc986X4-Xdprb5X8YhZg-8GgETMlMV3jRZGf5woBOQ-0eMce7Lyu7-Y7B_z_V7q_fGg7fsP-jng9f479hPpwSur89xufyilif0K57wXz18rAI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21160816</pqid></control><display><type>article</type><title>Neuroendocrine responses to levodopa in multiple system atrophy (MSA)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kimber, Jeffery ; Watson, Laura ; Mathias, Christopher J.</creator><creatorcontrib>Kimber, Jeffery ; Watson, Laura ; Mathias, Christopher J.</creatorcontrib><description>Hypothalamic dopaminergic pathways are involved in the regulation of growth hormone and prolactin release from the anterior pituitary. Neuroendocrine studies in patients with multiple system atrophy (MSA), in whom there is a reported loss of hypothalamic dopamine, are few and contradictory. We therefore studied the neuroendocrine responses to 250 mg levodopa (plus 25 mg carbidopa) in subjects with MSA (n = 15), and compared them with age‐ and sex‐matched healthy control subjects (n = 8). There were no significant differences in basal or post‐levodopa levels of growth hormone (GH), growth hormone‐releasing hormone (GHRH), glucose, insulin‐like growth factor (IGF‐1), or thyroid‐stimulating hormone (TSH) between the groups. In patients with MSA, basal levels of prolactin were elevated (21.1 ± 5.2 ng/mL [mean ± standard error]) compared with control subjects (12.1 ± 1.7, p <0.05), and after l‐dopa there was increased variability in prolactin response with less suppression compared with control subjects. In conclusion, in patients with MSA, the GHRH and GH responses to l‐dopa were preserved and were similar to responses in age‐matched control subjects. In contrast, there was impaired dopaminergic suppression of prolactin secretion. In patients with MSA this may represent a selective dysfunction, rather than generalized loss, of tubero‐infundibular dopaminergic neurones.</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/1531-8257(199911)14:6<981::AID-MDS1011>3.0.CO;2-W</identifier><identifier>PMID: 10584673</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Antiparkinson Agents - administration & dosage ; Antiparkinson Agents - adverse effects ; Biological and medical sciences ; Blood Glucose - metabolism ; Carbidopa ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dopamine - physiology ; Drug Combinations ; Female ; Growth Hormone-Releasing Hormone - blood ; Human Growth Hormone - physiology ; Humans ; Hypothalamo-Hypophyseal System - drug effects ; Hypothalamo-Hypophyseal System - physiopathology ; Insulin-Like Growth Factor I - metabolism ; Levodopa ; Male ; Medical sciences ; Middle Aged ; Multiple system atrophy ; Multiple System Atrophy - drug therapy ; Multiple System Atrophy - physiopathology ; Neuroendocrine ; Neurology ; Reference Values ; Thyrotropin - blood</subject><ispartof>Movement disorders, 1999-11, Vol.14 (6), p.981-987</ispartof><rights>Copyright © 1999 Movement Disorder Society</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4571-20f63807303707826d659bc270f2b83f539720223c6289fd04dac3e29c02b7553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F1531-8257%28199911%2914%3A6%3C981%3A%3AAID-MDS1011%3E3.0.CO%3B2-W$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F1531-8257%28199911%2914%3A6%3C981%3A%3AAID-MDS1011%3E3.0.CO%3B2-W$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1184165$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10584673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kimber, Jeffery</creatorcontrib><creatorcontrib>Watson, Laura</creatorcontrib><creatorcontrib>Mathias, Christopher J.</creatorcontrib><title>Neuroendocrine responses to levodopa in multiple system atrophy (MSA)</title><title>Movement disorders</title><addtitle>Mov. Disord</addtitle><description>Hypothalamic dopaminergic pathways are involved in the regulation of growth hormone and prolactin release from the anterior pituitary. Neuroendocrine studies in patients with multiple system atrophy (MSA), in whom there is a reported loss of hypothalamic dopamine, are few and contradictory. We therefore studied the neuroendocrine responses to 250 mg levodopa (plus 25 mg carbidopa) in subjects with MSA (n = 15), and compared them with age‐ and sex‐matched healthy control subjects (n = 8). There were no significant differences in basal or post‐levodopa levels of growth hormone (GH), growth hormone‐releasing hormone (GHRH), glucose, insulin‐like growth factor (IGF‐1), or thyroid‐stimulating hormone (TSH) between the groups. In patients with MSA, basal levels of prolactin were elevated (21.1 ± 5.2 ng/mL [mean ± standard error]) compared with control subjects (12.1 ± 1.7, p <0.05), and after l‐dopa there was increased variability in prolactin response with less suppression compared with control subjects. In conclusion, in patients with MSA, the GHRH and GH responses to l‐dopa were preserved and were similar to responses in age‐matched control subjects. In contrast, there was impaired dopaminergic suppression of prolactin secretion. In patients with MSA this may represent a selective dysfunction, rather than generalized loss, of tubero‐infundibular dopaminergic neurones.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiparkinson Agents - administration & dosage</subject><subject>Antiparkinson Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Carbidopa</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dopamine - physiology</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Growth Hormone-Releasing Hormone - blood</subject><subject>Human Growth Hormone - physiology</subject><subject>Humans</subject><subject>Hypothalamo-Hypophyseal System - drug effects</subject><subject>Hypothalamo-Hypophyseal System - physiopathology</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Levodopa</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple system atrophy</subject><subject>Multiple System Atrophy - drug therapy</subject><subject>Multiple System Atrophy - physiopathology</subject><subject>Neuroendocrine</subject><subject>Neurology</subject><subject>Reference Values</subject><subject>Thyrotropin - blood</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkV1v0zAUQC0EYmXwF1AeENoeUnzt-CMFIXXdOiZtq9CA8nblJo7ISOJgNxv996RKGDzwwpMl6_j4-piQFOgUKGVvQHCINRPqCNI0BTiGZCbfpRpms_nFaXx1egMU4D2f0uli9ZbF60dk8nDmMZlQrUXMQYsD8iyEW9rDAuRTcgBU6EQqPiFn17bzzja5y3zZ2Mjb0Lom2BBtXVTZO5e71kRlE9VdtS3bykZhF7a2jszWu_bbLjq6upkfPydPClMF-2JcD8nn5dmnxYf4cnV-sZhfxlkiFMSMFpJrqjjliirNZC5FusmYogXbaF4InipGGeOZZDotcprkJuOWpRllGyUEPySvB2_r3Y_Ohi3WZchsVZnGui4gA5BUg-zBjwOYeReCtwW2vqyN3yFQ3LfFfSfcd8KhLUKCEvu2iH1bHNsiR4qLFTJc986X4-Xdprb5X8YhZg-8GgETMlMV3jRZGf5woBOQ-0eMce7Lyu7-Y7B_z_V7q_fGg7fsP-jng9f479hPpwSur89xufyilif0K57wXz18rAI</recordid><startdate>199911</startdate><enddate>199911</enddate><creator>Kimber, Jeffery</creator><creator>Watson, Laura</creator><creator>Mathias, Christopher J.</creator><general>John Wiley & Sons, Inc</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>199911</creationdate><title>Neuroendocrine responses to levodopa in multiple system atrophy (MSA)</title><author>Kimber, Jeffery ; Watson, Laura ; Mathias, Christopher J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4571-20f63807303707826d659bc270f2b83f539720223c6289fd04dac3e29c02b7553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiparkinson Agents - administration & dosage</topic><topic>Antiparkinson Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Carbidopa</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dopamine - physiology</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Growth Hormone-Releasing Hormone - blood</topic><topic>Human Growth Hormone - physiology</topic><topic>Humans</topic><topic>Hypothalamo-Hypophyseal System - drug effects</topic><topic>Hypothalamo-Hypophyseal System - physiopathology</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Levodopa</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple system atrophy</topic><topic>Multiple System Atrophy - drug therapy</topic><topic>Multiple System Atrophy - physiopathology</topic><topic>Neuroendocrine</topic><topic>Neurology</topic><topic>Reference Values</topic><topic>Thyrotropin - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kimber, Jeffery</creatorcontrib><creatorcontrib>Watson, Laura</creatorcontrib><creatorcontrib>Mathias, Christopher J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kimber, Jeffery</au><au>Watson, Laura</au><au>Mathias, Christopher J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroendocrine responses to levodopa in multiple system atrophy (MSA)</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov. Disord</addtitle><date>1999-11</date><risdate>1999</risdate><volume>14</volume><issue>6</issue><spage>981</spage><epage>987</epage><pages>981-987</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>Hypothalamic dopaminergic pathways are involved in the regulation of growth hormone and prolactin release from the anterior pituitary. Neuroendocrine studies in patients with multiple system atrophy (MSA), in whom there is a reported loss of hypothalamic dopamine, are few and contradictory. We therefore studied the neuroendocrine responses to 250 mg levodopa (plus 25 mg carbidopa) in subjects with MSA (n = 15), and compared them with age‐ and sex‐matched healthy control subjects (n = 8). There were no significant differences in basal or post‐levodopa levels of growth hormone (GH), growth hormone‐releasing hormone (GHRH), glucose, insulin‐like growth factor (IGF‐1), or thyroid‐stimulating hormone (TSH) between the groups. In patients with MSA, basal levels of prolactin were elevated (21.1 ± 5.2 ng/mL [mean ± standard error]) compared with control subjects (12.1 ± 1.7, p <0.05), and after l‐dopa there was increased variability in prolactin response with less suppression compared with control subjects. In conclusion, in patients with MSA, the GHRH and GH responses to l‐dopa were preserved and were similar to responses in age‐matched control subjects. In contrast, there was impaired dopaminergic suppression of prolactin secretion. In patients with MSA this may represent a selective dysfunction, rather than generalized loss, of tubero‐infundibular dopaminergic neurones.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>10584673</pmid><doi>10.1002/1531-8257(199911)14:6<981::AID-MDS1011>3.0.CO;2-W</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 1999-11, Vol.14 (6), p.981-987 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21160816 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Antiparkinson Agents - administration & dosage Antiparkinson Agents - adverse effects Biological and medical sciences Blood Glucose - metabolism Carbidopa Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dopamine - physiology Drug Combinations Female Growth Hormone-Releasing Hormone - blood Human Growth Hormone - physiology Humans Hypothalamo-Hypophyseal System - drug effects Hypothalamo-Hypophyseal System - physiopathology Insulin-Like Growth Factor I - metabolism Levodopa Male Medical sciences Middle Aged Multiple system atrophy Multiple System Atrophy - drug therapy Multiple System Atrophy - physiopathology Neuroendocrine Neurology Reference Values Thyrotropin - blood |
| title | Neuroendocrine responses to levodopa in multiple system atrophy (MSA) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A14%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroendocrine%20responses%20to%20levodopa%20in%20multiple%20system%20atrophy%20(MSA)&rft.jtitle=Movement%20disorders&rft.au=Kimber,%20Jeffery&rft.date=1999-11&rft.volume=14&rft.issue=6&rft.spage=981&rft.epage=987&rft.pages=981-987&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/1531-8257(199911)14:6%3C981::AID-MDS1011%3E3.0.CO;2-W&rft_dat=%3Cproquest_cross%3E21160816%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21160816&rft_id=info:pmid/10584673&rfr_iscdi=true |